Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376637 | 1.00 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29687629 | 1.00 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL421253 | 0.98 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31309927 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557019 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31749859 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL178765 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL259018 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557247 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL1593608 | 0.95 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559529-B2 | NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| US-12054525-B2 | NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIOAL GMBH (DE) | 2024-08-06 | — | — | US | disclosed |
| EP-4399224-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | Sanofi (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-4192853-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | disclosed |
| EP-4110800-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-4058047-A1 | NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4021919-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021175974-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021127460-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021094259-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139548-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
| WO-2021041770-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2009022013-A1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139548-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | KMT2A 991/4885SMN1; SMN2 1118/4885LMNA 2884/4885 |
| US-12054525-B2 | NPY2 receptor agonists | NPY2R, NPY1R, NPY5R | KMT2A 991/4885SMN1; SMN2 1118/4885LMNA 2884/4885 |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1433/4885SMN1; SMN2 3778/4885LMNA 385/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1433/4885SMN1; SMN2 3778/4885LMNA 385/4885 |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | KMT2A 4159/4885SMN1; SMN2 3401/4885LMNA 4777/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | KMT2A 2259/4885SMN1; SMN2 1188/4885LMNA 3861/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | KMT2A 4035/4885SMN1; SMN2 3419/4885LMNA 4794/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1269/4885SMN1; SMN2 3368/4885LMNA 493/4885 |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | KMT2A 991/4885SMN1; SMN2 1118/4885LMNA 2884/4885 |
| US-12559529-B2 | NPY2 receptor agonists | NPY2R, NPY5R, NPY1R | KMT2A 679/4885SMN1; SMN2 1470/4885LMNA 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.